VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Prostate cancer DNA vaccine hPSMAt encoding PSMA
Vaccine Information
  • Vaccine Name: Prostate cancer DNA vaccine hPSMAt encoding PSMA
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004446
  • Type: DNA vaccine
  • Status: Research
  • Prostate-specific membrane antigen gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pVAX1 expressed human prostate-specific membrane antigen, PSMA (Mincheff et al., 2006).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000024
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Rat Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Only two of the 10 animals immunized against human PSMA developed tumors. In contrast, 17 of the 20 animals in the control groups developed tumors. The tumors, developing in the group, immunized with the human construct, were smaller than the ones in the control group (Mincheff et al., 2006).
References
Mincheff et al., 2006: Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer gene therapy. 2006; 13(4); 436-444. [PubMed: 16276349].